Sopharma has completed the initial stage of a strategic pharmaceutical portfolio acquisition

November 2024 — As part of Sopharma’s growth strategy to expand its regional market footprint, the company has recently completed the first stage of a transaction to acquire a large pharmaceutical product portfolio, including both consumer healthcare and prescription products.

Sopharma is a leading producer and distributor of pharmaceutical products in Europe and the Commonwealth of Independent States (CIS), operating with a vertically integrated business model that spans the entire value chain. The company is present in over 30 countries, with a combined revenue of €1 billion.

The pharmaceutical product portfolio acquired includes both consumer healthcare (CHC) and prescription products across diverse therapeutic areas such as sex hormones and modulators of the genital system, urologicals and antivirals for systemic use. Comprising 68 marketing authorizations, the portfolio features 14 well-known brands across 10 of Sopharma’s key markets. The transaction will be executed in stages, with the initial payment of €40 million secured by own funds and bank financing.

The seller is a European pharmaceutical company, which is developing, manufacturing and marketing a wide range of generic and over-the-counter (OTC) products.

Our role in the transaction

Oaklins’ team in Bulgaria advised Sopharma throughout the acquisition process, including transaction positioning and structuring, deal negotiations and execution.